|  |  |  |  |
| --- | --- | --- | --- |
| **Порядковый номер ссылки** | **Авторы, название публикации и источника, где она опубликована, выходные данные** | **ФИО, название публикации и источника на английском** | **Полный интернет-адрес (URL) цитируемой статьи или ее doi.** |
| 1 | Кудряшова А.М., Борисова О.В., Михайлова Н.А., Лоншаков Д.В., Катлинский А.В. Влияние методов иммобилизации эритропоэтина на чувствительность выявления специфических IgG антител в сыворотках крови экспериментальный животных. Журнал микробиологии эпидемиологии и иммунологии. 2017, 6:49-55. | Kudryashova A.M., Borisova O.V., Mikhaylova N.A., Lonshakov D.V., Katlinskiy A.V. Тhe effect of methods of immobilization of erythropoietin on the sensitivity for the detection of specific IgG antibodies to EPO in experimental animals sera, J. of Microbiology epidemiology and Immunobiology, 2017, vol.6 pp.49-55. | eLIBRARY ID: 37136201 |
| 2 | Barger T.E., Kuck A.J., Chirmule N. et al. Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol Dial. Transplant. 2012, vol. 27 pp. 688–693. | ----------- |  [10.1093/ndt/gfr213] |
| 3 | Barger T.E., Wrona D., GoletzT.J. et al. A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies. Nephrol. Dial Transplant. 2012, vol.27 no. 10 pp. 3892-3899. | ----------- |  [10.1093/ndt/gfs392] |
| 4 | Bennett C.L., Luminari S., Nissenson A.R. et al. Pure red-cell aplasia and epoetin therapy. N ngl J Med., 2004, vol. 351 pp.1403–1408. | ----------- | [10.1056/NEJMoa040528] |
| 5 | Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol. Dial.Transplant., 2002, 11 pp. 42-47. | ----------- | [10.1093/ndt/17.suppl\_5.42] |
| 6 | Casadevall N., Eckardt K.U., Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol. 2005, vol. 1 pp. 67–69. | ----------- | [10.1681/asn.2004110959] |
| 7 | Casadevall N., Nataf J., Viron B. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl. J. Med., 2002, vol. 346 pp. 469-475.  | ----------- | [10.1056/NEJMoa011931] |
| 8 | El-Din M., Attia F., Labib S., Omar W. Detection of circulating antierythropoietin antibodies in patients with end stage renal disease on regular hemodialysis. Int. J. Lab. Hematol., 2010, vol. 32 no. 3 pp. 336-343. | ----------- |  [10.1111/j.1751-553X.2009.01186.x] |
| 9 | Gross J., Moller R., Henke W. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J Immunol Methods, 2006, vol. 313 no. (1-2) pp. 176-82. | ----------- | [10.1016/j.jim.2006.04.008] |
| 10 | Guideline on immunogenicity assessment of therapeutic proteins. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), 2017. | ----------- | ----------- |
| 11 | Guideline on validation of bioanalytical methods (draft). European Medicines Agency. Committee for Medicinal Products of Human Use (CHMP), 2011. | ----------- | ----------- |
| 12 | Guideline Validation of analitical procedures (Q2 R1), ICH harmonised tripartite guideline, 2005. | ----------- | ----------- |
| 13 | Guidance for Industry: Bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, 2013. | ----------- | ----------- |
| 14 | Herrington W., Wieser C., Rosenkranz A.R. Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin. Kidney J., 2013, vol. 6 no.5 pp. 539–542. | ----------- | [10.1039/C5RA04950D] |
| 15 | Macdougall I.C., Casadevall N., Locatelli F., et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant**.,** 2015, vol. 3 no. 30, pp. 451–460. | ----------- | [10.1093/ndt/gfu297] |
| 16 | Macdougall I.C., Roger S.D., de Francisco A., et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis stimulating agents: new insights. Kidney Int**.,** 2012, vol. 8 no. 81 pp. 727-732. | ----------- | [10.1038/ki.2011.500]10.1093/ndt/gfu297 |
| 17 | Nakane P.K., Kawaoi A. J. Peroxidase-labeled antibody. A new method of conjugation. Histochem. Cytochem., 1974, vol. 22 no. 2 pp. 1084-1091. | ----------- |  [10.1177/22.12.1084] |
| 18 | Savash O. Alper G. Vecihi M. et al. Antierythropoietin Antibodies in Hemodialysis Patients Treated with Recombinant Erythropoietin. Turk Neph Dial Transpl., 2014, vol. 23 no. 2 pp.125-130. | ----------- | [10.5262/tndt.2014.1002.08] |
| 19 | Seidl A., Hainzl O., Richter M. et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res., 2012, vol. 29 no. 6 pp.1454-67. | ----------- | [10.1007/s11095-011-0621-4] |
| 20 | Shin S.K., Ha S.K., Lee KW. et al. Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera. J Pharm Biomed Anal. 2010, vol. 52 no. 2 pp. 289-93. | ----------- |  [10.1016/j.jpba.2010.01.022] |
| 21 | Weeraratne D.K., Kuck A.J., Chirmule N., Mytych D.T.Measurement of anti-erythropoiesis-stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell aplasia. Clin Vaccine Immunol. 2013, vol.20 no. 1 pp. 46-51. | ----------- | [10.1128/CVI.00435-12] |